Total Payments
$68,805
2024 Payments
$48,145
Companies
45
Transactions
489
Payment Breakdown by Category
Research$54,449 (79.1%)
Food & Beverage$9,244 (13.4%)
Travel$4,787 (7.0%)
Education$324.42 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $54,449 | 31 | 79.1% |
| Food and Beverage | $9,244 | 428 | 13.4% |
| Travel and Lodging | $4,787 | 18 | 7.0% |
| Education | $324.42 | 12 | 0.5% |
Payments by Type
Research
$54,449
31 transactions
General
$14,356
458 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $52,193 | 23 | $0 (2024) |
| Novo Nordisk AS | $6,544 | 23 | $0 (2022) |
| ABBVIE INC. | $1,319 | 25 | $0 (2024) |
| Janssen Research & Development, LLC | $1,162 | 9 | $0 (2023) |
| ViiV Healthcare Company | $993.81 | 44 | $0 (2024) |
| Gilead Sciences, Inc. | $796.94 | 32 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $628.10 | 37 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $535.16 | 33 | $0 (2023) |
| Novo Nordisk Inc | $475.81 | 24 | $0 (2024) |
| Allergan Inc. | $456.99 | 26 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48,145 | 51 | Eli Lilly and Company ($47,177) |
| 2023 | $2,250 | 44 | Janssen Research & Development, LLC ($1,162) |
| 2022 | $4,638 | 57 | Novo Nordisk AS ($3,841) |
| 2021 | $590.89 | 27 | Novo Nordisk Inc ($159.97) |
| 2020 | $1,574 | 16 | Eli Lilly and Company ($1,330) |
| 2019 | $3,578 | 86 | Novo Nordisk AS ($1,231) |
| 2018 | $5,180 | 115 | Eli Lilly and Company ($3,606) |
| 2017 | $2,849 | 93 | Novo Nordisk AS ($1,472) |
All Payment Transactions
489 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/29/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $28.29 | General |
| Category: RESPIRATORY | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $14.75 | General |
| Category: Respiratory | ||||||
| 10/08/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: Cardio-renal | ||||||
| 10/02/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $17.86 | General |
| Category: RESPIRATORY | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $35,562.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $8,197.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,113.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | ||||||
| 09/24/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.36 | General |
| 08/21/2024 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $240.54 | General |
| 08/09/2024 | Hologic Sales and Service, LLC | THINPREP 2000 PROCESSOR (Device) | Food and Beverage | In-kind items and services | $19.25 | General |
| Category: Diagnostics | ||||||
| 08/07/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $31.09 | General |
| Category: HIV | ||||||
| 07/30/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $27.51 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 07/23/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $25.19 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/11/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/20/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $18.26 | General |
| Category: NEUROSCIENCE | ||||||
| 06/19/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: NEUROSCIENCE | ||||||
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $339.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $320.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $118.73 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $51.79 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $51.01 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $42.98 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $32.96 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $32.96 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $32.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $35,562 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $8,197 | 1 |
| A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK | Eli Lilly and Company | $3,706 | 3 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $2,113 | 1 |
| NN9535-4321 & EX9924-4473 | Novo Nordisk AS | $1,615 | 7 |
| M16-100 | AbbVie, Inc. | $1,030 | 10 |
About Dr. Michael Jardula, MD
Dr. Michael Jardula, MD is a Internal Medicine healthcare provider based in Palm Springs, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1346222510.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Jardula, MD has received a total of $68,805 in payments from pharmaceutical and medical device companies, with $48,145 received in 2024. These payments were reported across 489 transactions from 45 companies. The most common payment nature is "" ($54,449).
Ad
Practice Information
- Specialty Internal Medicine
- Location Palm Springs, CA
- Active Since 11/15/2005
- Last Updated 12/28/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1346222510
Products in Payments
- Tresiba (Drug) $2,703
- Ozempic (Drug) $1,850
- Androgel (Drug) $1,070
- FARXIGA (Drug) $440.01
- XARELTO (Drug) $383.19
- DOVATO (Drug) $371.18
- VRAYLAR (Drug) $324.11
- ENTRESTO (Drug) $264.49
- SYMTUZA (Drug) $231.67
- PRADAXA (Drug) $230.18
- Symtuza (Drug) $212.80
- APRETUDE (Biological) $203.88
- JANUVIA (Drug) $191.92
- CABENUVA (Biological) $177.07
- ISENTRESS (Drug) $143.07
- UBRELVY (Drug) $132.59
- Otezla (Drug) $125.59
- STIOLTO (Drug) $125.38
- JULUCA (Drug) $124.61
- SYMBICORT (Drug) $113.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Palm Springs
Michael Bagheri, Md, MD
Internal Medicine — Payments: $37,109
Internal Medicine $37,109
Ann Stapleton, Md, MD
Internal Medicine — Payments: $34,455
Internal Medicine $34,455
Elber Camacho, Md, MD
Internal Medicine — Payments: $21,044
Internal Medicine $21,044
Dr. Dimple Agarwal, M.d, M.D
Internal Medicine — Payments: $18,144
Internal Medicine $18,144
Xolani Mdluli, Md, MD
Internal Medicine — Payments: $10,234
Internal Medicine $10,234
Kim Phan, D.o, D.O
Internal Medicine — Payments: $7,952
Internal Medicine $7,952